-Economic and Political Weekly The Supreme Court judgment on the Novartis-Glivec case is remarkable because it has gone beyond the specific technical and legal issues surrounding patents and has put the matter in a much larger political and economic perspective. The deeper implication of the judgment is that it is not only justified to deny patents when incremental innovation is trivial as in the Glivec case. The judgment has linked the...

-The Times of India The enforcement directorate's probe into alleged money laundering by the scam-scarred Saradha group may cover important politicians and their kin, besides media professionals, exposing them to the risk of confiscation of their bank accounts and properties. Sources in the ED, which has already registered a case in Guwahati, said the agency will issue summons to all those who helped siphon off money that Saradha had mopped up from...

-The Times of India The National Advisory Council (NAC) on Friday approved mandatory public consultation on new laws and rules before they are brought to Parliament. This will for the first time provide an institutional structure for civil society representatives to express their views. The "pre-legislative process'' was brought in the wake of increasing dissatisfaction over legislations piloted by the government, especially the Lokpal Bill. The move was initiated by NAC...

-The Times of India MUMBAI: You could be popping certain pills and combinations that are illegally approved, harmful, cleared without proper clinical trials or even banned in the US and other countries. Delivering a severe rap on the government's knuckles, a parliamentary standing committee on health has charged it with "dilly-dallying and procrastination'' over serious irregularities in approval of life-saving medicines, not following the global ban on harmful drugs, and failing...

-Economic and Political Weekly While the Supreme Court decision in the recent Novartis case has cleared the way for production of generic drugs in India, doctors have to prescribe cheaper alternatives to costly brands if patients with limited means are to benefit. What is being hailed as a victory in the struggle for affordable medicines in the country will actually be one only when there is a pro-patient slant to the...